B&K Corp Ltd

B&K Corporation Limited is a biopharmaceutical company focused on developing protein-based therapies for medical needs and market opportunities in China. Its main focus is on wound healing, particularly platelet-derived growth factor (PDGF) drugs. The pipeline includes two core products: Pro-101-1 for deep second-degree thermal burns (completed Phase IIb statistical analysis) and superficial second-degree thermal burns, and Pro-101-2 for diabetic foot ulcers. Additional products target acute and chronic wounds, including thermal burns, DFUs, fresh wounds, pressure ulcers, radiation ulcers, dry eye syndrome, corneal injury, photodermatitis, alopecia, hemorrhoids, and gastric ulcers. The company was formerly known as Beijing Zhonghong Saisi Biotechnology Limited and changed its name to B&K Corporation Limited in April 2024. Founded in 2012, it is based in Qingdao, China.